Both are highly effective. The differences — in how they work, how much weight loss to expect, side effects, cost, and insurance coverage — matter for choosing the right one for your situation.
Bottom line up front: Tirzepatide produces greater average weight loss in clinical trials. Semaglutide has a longer safety record, broader insurance coverage, and is the established first-line choice for many prescribers. The best medication is the one you can tolerate, afford, and stay on — both are excellent options.
Both medications are injectable GLP-1 receptor agonists — they mimic the GLP-1 hormone that regulates appetite and blood sugar. But tirzepatide goes further:
| Semaglutide | Mechanism | Tirzepatide |
|---|---|---|
| ✓ Activates GLP-1 receptor | GLP-1 agonism | ✓ Activates GLP-1 receptor |
| — | GIP agonism | ✓ Also activates GIP receptor |
| Slows gastric emptying, reduces appetite, improves blood sugar | Primary effects | All semaglutide effects, plus enhanced insulin secretion and fat cell metabolism via GIP |
| Single hormone target | Classification | Dual hormone target ("twincretin") |
The GIP receptor activation is believed to be the primary reason tirzepatide produces greater weight loss — GIP enhances the GLP-1 effects and may have additional metabolic benefits in fat tissue.
| Metric | Semaglutide (STEP-1) | Tirzepatide (SURMOUNT-1) |
|---|---|---|
| Average weight loss | 14.9% body weight | 20.9% body weight (15mg dose) |
| ≥5% weight loss achieved | ~86% of participants | ~91% of participants |
| ≥15% weight loss achieved | ~32% of participants | ~57% of participants (15mg) |
| ≥20% weight loss achieved | ~12% of participants | ~36% of participants (15mg) |
| Duration of main trial | 68 weeks | 72 weeks |
| Cardiovascular outcomes data | SELECT trial: 20% reduction in major CV events (Wegovy, high-risk patients) | SURPASS-CVOT trial: positive CV outcomes data for Mounjaro |
| Head-to-head trial | SURMOUNT-5 (2025): tirzepatide produced ~47% more weight loss than semaglutide on average | |
Important context: Trial averages hide wide individual variation. Some people lose 5% on tirzepatide and 25% on semaglutide. Response is highly individual and influenced by genetics, starting weight, lifestyle factors, and dose. The "best" drug is the one that works for you specifically — which often requires trying one.
The side effect profiles are similar — both cause GI symptoms through the same gastric emptying mechanism. There are some meaningful differences:
| Side Effect | Semaglutide | Tirzepatide | Edge |
|---|---|---|---|
| Nausea | ~44% | ~31% | Tirzepatide |
| Diarrhea | ~30% | ~23% | Tirzepatide |
| Vomiting | ~9% | ~6% | Tirzepatide |
| Constipation | ~11% | ~17% | Semaglutide |
| Injection site reactions | ~3% | ~7% | Semaglutide |
| Discontinuation due to GI side effects | ~4–5% | ~3–4% | Similar |
| Heart rate increase | ~1–4 bpm average | ~1–4 bpm average | Similar |
| Years of safety data | ~7 years (Ozempic since 2017) | ~3 years (Mounjaro since 2022) | Semaglutide |
Rates from STEP-1 and SURMOUNT-1 trials. Direct comparison is approximate — trials used different populations and protocols.
The same molecule can have multiple brand names depending on the FDA-approved indication. This matters significantly for insurance coverage — your diagnosis determines which brand name applies, which determines whether your plan covers it.
| Coverage Scenario | Semaglutide | Tirzepatide |
|---|---|---|
| Brand-name retail price (list) | ~$936/mo (Ozempic) · ~$1,350/mo (Wegovy) | ~$1,023/mo (Mounjaro) · ~$1,060/mo (Zepbound) |
| Manufacturer savings card (T2D, commercially insured) | Ozempic: as low as $25/mo | Mounjaro: as low as $25/mo |
| Manufacturer savings card (obesity indication) | Wegovy: as low as $0 (eligible patients) | Zepbound: as low as $25/mo (eligible patients) |
| Commercial insurance (diabetes) | Widely covered (Ozempic) | Widely covered (Mounjaro) |
| Commercial insurance (obesity) | Covered by ~50% of plans (Wegovy) | Growing, fewer plans cover vs. Wegovy (Zepbound) |
| Medicare Part D (diabetes) | Covered (Ozempic) | Covered (Mounjaro) |
| Medicare (obesity/weight loss) | Wegovy covered for established CVD (SELECT trial indication) | Zepbound not yet covered for weight loss |
| Telehealth / compounded (self-pay) | $150–$350/mo typical range | $175–$400/mo typical range |
Coverage advantage to semaglutide (Wegovy) for Medicare patients: The SELECT trial demonstrated Wegovy reduces major cardiovascular events by 20% in high-risk patients. Medicare covers it for patients with established cardiovascular disease — a coverage pathway that Zepbound does not yet have. If you're on Medicare with a CV history, semaglutide may be your only covered option for obesity treatment.
Both Ozempic (semaglutide) and Mounjaro (tirzepatide) are FDA-approved for T2D and widely covered. Tirzepatide shows superior A1C reduction in trials. Your endocrinologist or PCP will guide this choice.
Either — ask your prescriberWegovy (semaglutide) has the cardiovascular risk reduction coverage pathway under Medicare Part D. Zepbound is not yet covered for weight loss. For weight loss under Medicare, semaglutide is your covered option.
Semaglutide (Wegovy)Many insurers require trying a semaglutide product before approving tirzepatide. In this case, starting with semaglutide is required — and many people find they get the results they need without ever needing to switch.
Semaglutide firstIf achieving the largest possible weight reduction is the clinical goal — and cost and coverage are not barriers — tirzepatide's trial data shows meaningfully superior outcomes on average.
TirzepatideSome patients who struggle with nausea on semaglutide tolerate tirzepatide better — the GI side effect profile is slightly different. Switching is a legitimate clinical option.
Try tirzepatideCompounded versions of both are comparably priced through telehealth programs. If compounding availability changes (FDA shortage status), one may be more available than the other at a given time.
Either — check current availabilityOzempic has been on the market since 2017 — nearly a decade of real-world safety data across millions of patients. Mounjaro has been available since 2022. If long-term safety data is a priority, semaglutide has the edge.
SemaglutideClinical data and prescriber experience suggest some patients who are "semaglutide low-responders" respond better to tirzepatide's dual mechanism. Switching is a reasonable next step.
Try tirzepatideYour prescriber will have a default preference based on their clinical experience and your diagnosis. Here's how to have a productive conversation:
| Your situation | What to say |
|---|---|
| You want maximum weight loss | "I've read that tirzepatide shows higher average weight loss in trials like SURMOUNT-1 vs. STEP-1. Is that an option for me given my insurance?" |
| You had nausea problems before | "I've read tirzepatide may have slightly lower nausea rates. Could we try that, or start lower and slower on the escalation schedule?" |
| Your insurer covers only one | "My plan covers [drug]. Can we start there and revisit if I don't get adequate response at the maintenance dose?" |
| You're not responding to current medication | "I've been on [drug] for [X months] at the [dose] dose and my response has plateaued at [X%]. Would switching to the other molecule make clinical sense?" |
Yes — switching between the two is clinically feasible and done regularly. Most prescribers start at a lower dose of the new medication to allow adjustment. The most common switch is from semaglutide to tirzepatide when patients want to try for greater weight loss or had tolerability issues. Switching in the opposite direction is less common but also done — for example, if tirzepatide causes constipation that semaglutide didn't.
Often, yes. The dual GIP/GLP-1 mechanism means tirzepatide operates somewhat differently at the cellular level. Clinical experience suggests meaningful "semaglutide non-responders" do achieve results on tirzepatide. This is increasingly a supported clinical pathway — trying the alternative molecule after inadequate response to the first.
Availability depends on FDA shortage status, which changes over time. Both have been available as compounded medications through licensed telehealth programs during shortage periods. Check with your specific program about current availability, as this can change. See our Compounded GLP-1 Guide for quality and sourcing details.
Both are FDA-approved for Type 2 diabetes. Head-to-head trial data shows tirzepatide achieves greater A1C reduction on average. The SURPASS-2 trial found tirzepatide reduced A1C by up to 2.6 percentage points vs. 2.0 for semaglutide. For patients where A1C control is a primary concern, many endocrinologists now prefer tirzepatide — subject to coverage and patient factors.
This page is for informational purposes only and does not constitute medical advice. Medication selection should be made in consultation with a qualified healthcare provider who knows your full medical history. Trial data cited: STEP-1 (NEJM 2021), SURMOUNT-1 (NEJM 2022), SURMOUNT-5 (2025), SELECT (NEJM 2023), SURPASS-2 (NEJM 2021).